OptiBiotix Health PLC (LON:OPTI)

OptiBiotix Health PLC (LON:OPTI)

Share Price
74.22 p
0.22 (0.30 %)
Market Cap
£63.41 m
Proactive Investors - Run By Investors For Investors

OptiBiotix Health PLC RNS Release

GoFigure® distribution agreement for Poland

RNS Number : 7617Z
OptiBiotix Health PLC
22 May 2019

OptiBiotix Health plc



GoFigure® distribution agreement for Poland


OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol and diabetes, announces it has appointed Extensor as its exclusive distributor of OptiBiotix's own label GoFigure® consumer weight management products in Poland.


The agreement grants Extensor the exclusive rights to import, market and distribute OptiBiotix's GoFigure® range of meal replacements, flapjacks and mueslis containing its award winning SlimBiome® technology within the Polish market. This agreement has been signed accompanied by an initial modest five figure order and registration of gofigure.pl for online promotion of the products within the Polish market. 


Extensor is a well-known Polish brand that was established over 19 years ago for the creation and promotion of products with the highest quality and safety levels in the Health and Wellness sector. The company works with world leaders in the whey protein industry and in 2002, introduced high-protein supplements to the Polish market. Extensor has an extensive distribution network across Poland and is sold through multiple on-line channels, wholesalers, and retail outlets across shops in Poland.


This agreement is a strategic step to take OptiBiotix's own label GoFigure® products to international marketsThis builds GoFigure® brand recognition, enhancing brand value, and creates a further demand for SlimBiome®, the functional ingredient within Gofigure® products. 


Christina Wood, Sales & Marketing Director commented: "We are pleased to announce this exclusive distribution deal for the commercialisation of our GoFigure® products in the Polish market.  This is part of a commercial strategy of working across multiple levels of the value chain (manufacturer, formulator and distributor) for the supply of white label and own label branded products. This is the first step in taking OptiBiotix's own label GoFigure® products to international markets. This increases brand recognition and value in addition to creating a demand for SlimBiome®, the functional ingredient within GoFigure® products. This means we are able to derive revenue from both the sale of our own brand GoFigure® products and SlimBiome®."


This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.


For further information, please contact:


OptiBiotix Health plc


Stephen O'Hara, Chief Executive

Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner


finnCap (Broker)


Tel: 020 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)

Camille Gochez (Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Anna Dunphy

Mob: 07876 741 001





About OptiBiotix - www.optibiotix.com 


OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 


OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.


OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 






This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

OptiBiotix Health PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use